According to Fintel, on May 16, 2023, HC Wainwright & Co. reiterated its coverage of Onconova Therapeutics (NASDAQ:ONTX) with a Buy recommendation. The one-year price target for Onconova Therapeutics as of May 11, 2023, is expected to increase by 548.31% from its latest reported closing price of 1.18.
Other details show that the projected annual revenue for Onconova Therapeutics is for 0MM, a decrease of 1.76%, while the projected annual non-GAAP EPS is -1.31.
The put/call ratio of ONTX is 0.01, indicating a bullish outlook. There are 35 funds or institutions reporting positions in Onconova Therapeutics, which is a decrease of 3 owner(s) or 7.89% in the last quarter. Average portfolio weight of all funds dedicated to ONTX is 0.00%, a decrease of 7.91%. Total shares owned by institutions decreased to 1,457K shares in the last three months by 15.25%.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 366K shares representing 1.74% ownership of the company, while VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 237K shares representing 1.13% ownership of the company. Geode Capital Management holds 170K shares representing 0.81% ownership of the company. Renaissance Technologies holds 145K shares representing 0.69% ownership of the company.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Source: Fintel.
The opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
